症状性感染胎儿孕妇中人巨细胞病毒游离DNA的检测:概念验证研究
该概念验证研究纳入9例原发性或非原发性母体感染后胎儿诊断为先天性巨细胞病毒(cCMV)的孕妇,检测母体血浆CMV游离DNA(cfDNA)。所有病例均可检出CMV-cfDNA;11–13周样本多为低水平,cCMV诊断时样本持续为高水平。作者认为早孕期低水平CMV-cfDNA可能是严重胎儿cCMV的生物标志物,但许多孕妇早孕期即可检出,需进一步研究确定其预测价值。
要点
- 9例胎儿cCMV孕妇中,母体血浆CMV-cfDNA全部可检出。
- 11–13周样本多为低水平CMV-cfDNA,cCMV诊断时样本持续为高水平。
- 1例终止妊娠后30分钟和12小时样本CMV-cfDNA较术前大幅下降。
核心结论
- 11–13周检出的低水平CMV-cfDNA可能是严重胎儿cCMV的生物标志物。
- 早孕期CMV-cfDNA分析可能对CMV筛查有附加价值,尤其对无法用其他方法识别的非原发性母体感染。
- 由于许多孕妇早孕期即可检出CMV-cfDNA,需进一步研究确定其作为严重胎儿cCMV生物标志物的预测价值。
- 胎儿cCMV诊断时高水平和终止妊娠后即刻低水平的CMV-cfDNA提示,母体血浆CMV-cfDNA水平未必反映活动性母体感染,而可能提示胎盘感染。
研究设计与样本
- 研究纳入2019年6月至2024年7月间9例胎儿诊断为cCMV的孕妇,诊断孕周为20+4至34+1周(n=8)或新生儿期(n=1),母体感染为原发性或非原发性。
- 8例分析单个时间点的cfDNA测序数据:5例回顾性分析11–13周数据,3例在cCMV诊断时前瞻性分析20–26周数据。
- 1例(病例6)在四个时间点进行CMV-cfDNA分析:12+5周(常规无创产前检测)、23+3周(cCMV诊断)、以及23+6周终止妊娠后30分钟和12小时。
主要发现
- 所有病例均可检出CMV-cfDNA。
- 11–13周采集的样本中CMV-cfDNA多为低水平,cCMV诊断时采集的样本中CMV-cfDNA持续为高水平。
- 病例6终止妊娠后检测的样本中母体CMV-cfDNA水平较终止妊娠前样本大幅下降。
临床怎么用
- 早孕期CMV-cfDNA分析可能对CMV筛查有附加价值,尤其对无法用其他方法识别的非原发性母体感染。
- 由于许多孕妇早孕期即可检出CMV-cfDNA,需进一步研究确定其作为严重胎儿cCMV生物标志物的预测价值。
局限性
- 由于许多孕妇早孕期即可检出CMV-cfDNA,需进一步研究确定其作为严重胎儿cCMV生物标志物的预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the presence and levels of cytomegalovirus (CMV) cell-free DNA (cfDNA) fragments in women pregnant with a fetus with symptomatic congenital CMV (cCMV). METHODS: The study comprised nine women whose fetuses were diagnosed with cCMV between June 2019 and July 2024 at 20 + 4 to 34 + 1 weeks' gestation (n = 8) or neonatally (n = 1) after primary or non-primary maternal infection. In eight women, cfDNA sequencing data from a single timepoint were analyzed, either retrospectively, on data generated from 11-13 weeks' gestation (n = 5) or prospectively, on data generated from 20-26 weeks' gestation (n = 3), upon the diagnosis of cCMV. In one woman (Case 6), CMV-cfDNA analysis was performed at four timepoints: at 12 + 5 weeks (routine non-invasive prenatal testing); 23 + 3 weeks (cCMV diagnosis); and 30 min and 12 h after termination of pregnancy (TOP) at 23 + 6 weeks. RESULTS: CMV-cfDNA was detectable in all cases. Mostly low levels of CMV-cfDNA were observed in samples obtained at 11-13 weeks' gestation and consistently high levels of CMV-cfDNA were present in samples obtained at cCMV diagnosis. In Case 6, the level of maternal CMV-cfDNA decreased substantially in the samples tested after TOP, compared with samples obtained before TOP. CONCLUSIONS: Low levels of CMV-cfDNA detected between 11 and 13 weeks may be a biomarker for severe fetal cCMV. CMV-cfDNA analysis in the first trimester could be of added value in CMV screening, particularly for non-primary maternal infections that cannot be identified using other methods. However, as CMV-cfDNA is detectable in many pregnant women in the first trimester, further studies are needed to determine the predictive value of CMV-cfDNA as a biomarker for the development of severe fetal cCMV. High levels of CMV-cfDNA at fetal cCMV diagnosis and low levels directly after TOP suggest that the level of CMV-cfDNA in maternal plasma may not necessarily reflect an active maternal infection, but could indicate a placental infection. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Faas BHW, Meuleman T, Astuti G, et al. Detection of human cytomegalovirus cell-free DNA in pregnant women with symptomatically infected fetuses: proof-of-concept study. Ultrasound Obstet Gynecol. 2025. PMID: 40033519. doi:10.1002/uog.29199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。